PT3802517T - Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose - Google Patents

Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose

Info

Publication number
PT3802517T
PT3802517T PT197311632T PT19731163T PT3802517T PT 3802517 T PT3802517 T PT 3802517T PT 197311632 T PT197311632 T PT 197311632T PT 19731163 T PT19731163 T PT 19731163T PT 3802517 T PT3802517 T PT 3802517T
Authority
PT
Portugal
Prior art keywords
fibrosis
alkoxy
treatment
receptor antagonists
substituted pyridinyl
Prior art date
Application number
PT197311632T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PT3802517T publication Critical patent/PT3802517T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PT197311632T 2018-06-07 2019-06-05 Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose PT3802517T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07

Publications (1)

Publication Number Publication Date
PT3802517T true PT3802517T (pt) 2023-03-20

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197311632T PT3802517T (pt) 2018-06-07 2019-06-05 Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose

Country Status (22)

Country Link
US (1) US12344597B2 (enExample)
EP (1) EP3802517B1 (enExample)
JP (1) JP7386183B2 (enExample)
KR (1) KR102826034B1 (enExample)
CN (1) CN112236424B (enExample)
AU (1) AU2019282274A1 (enExample)
BR (1) BR112020024879A2 (enExample)
CA (1) CA3102683A1 (enExample)
DK (1) DK3802517T3 (enExample)
EA (1) EA202092955A1 (enExample)
ES (1) ES2940695T3 (enExample)
FI (1) FI3802517T3 (enExample)
HR (1) HRP20230243T1 (enExample)
HU (1) HUE061559T2 (enExample)
LT (1) LT3802517T (enExample)
MX (1) MX2020013291A (enExample)
PL (1) PL3802517T3 (enExample)
PT (1) PT3802517T (enExample)
RS (1) RS63990B1 (enExample)
SI (1) SI3802517T1 (enExample)
TW (1) TW202016090A (enExample)
WO (1) WO2019234115A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) * 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
FI20225388A1 (en) * 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
AU2008311971A1 (en) 2007-10-18 2009-04-23 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EP2297153B1 (en) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
JP5708936B2 (ja) 2009-09-25 2015-04-30 アステラス製薬株式会社 置換アミド化合物
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Also Published As

Publication number Publication date
KR102826034B1 (ko) 2025-06-27
KR20210018900A (ko) 2021-02-18
CN112236424A (zh) 2021-01-15
BR112020024879A2 (pt) 2021-03-09
CA3102683A1 (en) 2019-12-12
WO2019234115A1 (en) 2019-12-12
JP7386183B2 (ja) 2023-11-24
AU2019282274A1 (en) 2021-01-28
EA202092955A1 (ru) 2021-04-08
FI3802517T3 (fi) 2023-03-23
PL3802517T3 (pl) 2023-05-22
US12344597B2 (en) 2025-07-01
US20210246116A1 (en) 2021-08-12
TW202016090A (zh) 2020-05-01
CN112236424B (zh) 2024-03-15
LT3802517T (lt) 2023-03-10
EP3802517B1 (en) 2022-12-21
MX2020013291A (es) 2021-04-29
ES2940695T3 (es) 2023-05-10
RS63990B1 (sr) 2023-03-31
HRP20230243T1 (hr) 2023-04-14
JP2021527046A (ja) 2021-10-11
HUE061559T2 (hu) 2023-07-28
EP3802517A1 (en) 2021-04-14
DK3802517T3 (da) 2023-03-13
SI3802517T1 (sl) 2023-04-28

Similar Documents

Publication Publication Date Title
SG11202106144VA (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
LT3675854T (lt) Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti
IL272016A (en) Pyrrolidine history and their use as TLR7/8 antagonists
PL4424364T3 (pl) Kombinacje do stosowania w leczeniu marskości wątroby i zwłóknienia wątroby
IL277694A (en) Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine
SI3802517T1 (sl) Alkoksi-substituirani piridinilni derivati kot antagonisti receptorja LPA1 in njihova uporaba pri zdravljenju fibroze
IL280479A (en) Tlr7/8 antagonists and their use
ZA201906904B (en) Therapeutic agent for phosphodiesterase inhibition and its related disorders
SI4076652T1 (sl) Farmacevtsko sprejemljiva sol atrazentana za uporabo v zdravljenju iga nefropatije
LT4014976T (lt) Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
IL289164A (en) The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
IL285025A (en) History of heterocyclic carboxamides, their preparation and use
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
IL281100A (en) Methods of modulating m2 macrophage polarization and use of same in therapy
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
IL282527A (en) 5-Azaindazole history and their use
SG11202010985TA (en) Heterocyclic derivatives and use thereof
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
IL282526A (en) 5-Azaindazole history and their use
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
IL278009A (en) History of 6,2-diamino-4,3-dihydropyrimidin-4-one and its use in treatment